News about "Aurobindo Pharma"

Aurobindo Pharma Gets US FDA Approval for Perampanel Tablets

Aurobindo Pharma has received US FDA final approval for Perampanel Tablets, 2 mg to 12 mg, equivalent to Fycompa Tablets.

Aurobindo Pharma | 06/10/2026 | By News Bureau |  174

Aurobindo Pharma receives US FDA Final Approval for Beclomethasone Dipropionate HFA Inhalation Aerosol, 40 mcg and 80 mcg

Aurobindo Pharma receives US Food and Drug Administration (FDA) final approval for Beclomethasone Dipropionate HFA Inhalation Aerosol, marking its first Metered-Dose Inhaler (MDI) product and expanding its complex respiratory portfolio.

Aurobindo Pharma | 16/09/2026 | By News Bureau

Aurobindo Pharma's API Facility Receives Zero Observations in US FDA Inspection

Aurobindo Pharma said the US FDA inspection of its API manufacturing facility in Pydibhimavaram, Andhra Pradesh, concluded with zero observations.

Aurobindo Pharma | 15/09/2026 | By News Bureau

Aurobindo Pharma's Lannett Launches Generic Advair Diskus in US

Aurobindo Pharma’s Lannett launches generic Advair Diskus in the US in 100/50 mcg and 250/50 mcg strengths for asthma and COPD treatment.

Aurobindo Pharma | 31/08/2026 | By News Bureau

Is Pharma Packaging Keeping Pace with Drug Innovation?

As therapies grow more complex, packaging is evolving beyond protection to enable drug delivery, safety, and adherence. Pharma Industrial India explores emerging technologies and innovations shaping future-ready pharma packaging.

Aurobindo Pharma | 25/08/2026 | By News Bureau |  127

Aurobindo Pharma's Lannett Facility Completes US FDA Inspection with 4 Observations

Aurobindo Pharma’s Lannett facility in Indiana completes a US Food and Drug Administration (FDA) inspection with 4 procedural observations and will respond within the stipulated timeline.

Aurobindo Pharma | 24/08/2026 | By News Bureau

Aurobindo Pharma's Raleigh Plant Receives VAI Classification from US FDA

Aurobindo Pharma’s Raleigh plant receives Voluntary Action Indicated (VAI) classification from the US Food and Drug Administration (FDA), closing the inspection and allowing pending inhaler and dosage-form applications to progress.

Aurobindo Pharma | 17/08/2026 | By News Bureau |  131

Aurobindo Pharma Unit Receives US FDA Warning Letter; No Impact on US Supplies

Aurobindo Pharma’s Eugia Pharma Specialities has received a US FDA warning letter for its Telangana facility, while the company said existing US supplies remain unaffected.

Aurobindo Pharma | 14/08/2026 | By News Bureau |  222

Aurobindo Pharma's Eugia Unit I Receives US FDA Warning Letter

Aurobindo Pharma’s Eugia Pharma Unit I receives a US Food and Drug Administration (FDA) Warning Letter following OAI status, with no impact on existing US supplies.

Aurobindo Pharma | 14/08/2026 | By News Bureau |  298

Aurobindo Pharma Approves Merger of Eugia Subsidiaries to Streamline Business Operations

Aurobindo Pharma has approved the merger of two step-down subsidiaries into Eugia Pharma Specialities, a move aimed at consolidating similar businesses, reducing administrative costs and strengthening operational efficiency.

Aurobindo Pharma | 07/08/2026 | By News Bureau |  215